Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases

Sodium-glucose cotransporter 2 (SGLT2) inhibitor have become widely used in patients with diabetes, heart failure, and kidney disease to improve clinical outcomes and diminish hospitalizations. They have also been associated with increased serum magnesium levels in patients with type 2 diabetes. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Chintan V., Robbins, T. Scott, Sparks, Matthew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519375/
https://www.ncbi.nlm.nih.gov/pubmed/36185705
http://dx.doi.org/10.1016/j.xkme.2022.100533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519375/
https://www.ncbi.nlm.nih.gov/pubmed/36185705
http://dx.doi.org/10.1016/j.xkme.2022.100533

Ejemplares similares